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Background: Flotillin-2 (FLOT2) has been implicated in several signaling pathways in tumor cells. Our study aimed
to investigate the expression pattern and clinicopathological significance of FLOT2 in patients with breast cancer.
Methods: The expression level of FLOT2 in normal breast epithelial cells, breast cancer cell lines, and four breast
cancer biopsies paired with adjacent noncancerous tissues were quantified using real-time RT-PCR and Western
blotting. FLOT2 protein expression was analyzed in 171 archived paraffin-embedded breast cancer samples using
immunohistochemistry (IHC). Statistical analyses were performed to evaluate the clinicopathological significance of
FLOT2 expression.
Results: FLOT2 was significantly upregulated in breast cancer cell lines and tissue samples compared with normal
cells and adjacent noncancerous breast tissues, respectively. IHC analysis revealed high expression levels of FLOT2 in
82 of 171 (48.0%) breast cancer specimens. Statistical analysis revealed that FLOT2 expression was significantly
correlated with clinical stage (P < 0.001), T classification (P < 0.001), M classification (P < 0.001), histological
differentiation (P = 0.005) and ErbB2 expression (P = 0.003). Patients with higher levels of FLOT2 expression had a
shorter overall survival duration than patients with lower FLOT2 expression levels. Multivariate analysis suggested
that FLOT2 expression was an independent prognostic marker for survival in patients with breast cancer.
Conclusions: The current results demonstrated that high FLOT2 protein expression was associated with poor
outcomes in patients with breast cancer. FLOT2 could be used as a prognostic biomarker for breast cancer
progression.
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Breast cancer is the leading cause of cancer-related
death in women worldwide, accounting for 23% of all
new cancer cases and 14% of the total cancer deaths [1].
The etiological factors associated with breast cancer in-
clude both genetic and environmental factors. Altered
expression levels of oncogenes and tumor suppressor
genes have been found in breast cancer, but no specific
signature of breast cancer gene expression has been
reported to enable entirely individualized treatment
strategies. In clinical practice, conventional pathological* Correspondence: linhuanxin13@gmail.com
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reproduction in any medium, provided the orvariables, including tumor size, nodal involvement and
the depth of infiltration are extensively used to predict
prognosis [2-5]. However, traditional pathological vari-
ables are not sufficiently reliable to predict clinical out-
comes or to guide optimal treatment strategies. Recently,
it has been reported that the molecular portraits revealed
in gene expression patterns may lead to a deeper and
more comprehensive understanding of breast cancer types
[6]. Hence, the discovery of novel biomarkers involved in
the diagnosis and progression of breast cancer is of great
value in identifying high-risk patients who may benefit
from more aggressive primary surgery, or adjuvant treat-
ment following surgery, and in providing novel thera-
peutic targets.
FLOT2, a major protein on lipid rafts, is a highly con-
served 47-kDa protein which was initially identified as a
protein that was upregulated during axon regenerationtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in a number of cellular mechanisms that are dysregulated
in tumor cells, such as altered protein signaling and traf-
ficking, it is possible that abnormalities of FLOT2 protein
contribute to the formation of cancer-specific cellular
characteristics [9-11]. In 2000, Charles et al. identified a
cluster of ER low-expression breast tumors that were par-
tially characterized by the high level of expression of a
specific subset of genes, including FLOT2 protein using
cDNA microarrays [6]. FLOT2 overexpression has been
reported to be associated with human melanoma progres-
sion and the development of metastasis in human head
and neck squamous cell carcinomas [12,13]. Pust et al.
reported that FLOT2, together with flot-1, Hsp90 and
ErbB2, acted as a complex in breast cancer, and revealed
that flotillins are implicated in the stabilization of ErbB2
at the plasma membrane [14]. They also showed that
FLOT2 may serve as a potential predictor of prognosis in
early-stage breast cancer by microarray analyses [14].
Shortly afterwards, FLOT2 was reported as a significant
regulator of mammary tumor-derived lung metastasis
[15]. However, the clinical significance of FLOT2 in breast
cancer remains unclear.
In the present study, we found that the expression of
FLOT2 was upregulated in breast cancer cells and surgical
specimens of breast cancer. Moreover, the overexpression
of FLOT2 in breast cancer is associated with the clinical
stage, T and M classification, histological differentiation
and ErbB-2 expression levels. Multivariate analysis re-
vealed that FLOT2 might be an independent biomarker
for the prediction of breast cancer prognosis. Taken to-
gether, our results suggest that FLOT2 plays a significant




Primary normal mammary epithelial cells (NMEC) were
established according to a previous report [16]. Breast
cancer cell lines, including BT-549, MDA-MB-468, MDA-
MB-453, Bcap37, MCF-7, T47D, ZR-75-1 and MDA-MB-
231 were cultured in DMEM medium (Gibco, Grand
Island, NY, USA) supplemented with 10% FBS (HyClone,
Logan, UT, USA).
Clinical samples and clinical staging system
This study was conducted on a total of 171 paraffin-
embedded breast cancer samples, which were histo-
pathologically and clinically diagnosed at the Sun Yat-sen
University Cancer Center between 1998 and 2005. Clinical
and clinicopathological classification and staging were de-
termined according to the American Joint Committee on
Cancer (AJCC) criteria. Patient consent was gained prior
to the use of these clinical materials for research purposes,prior patients’ consents, and the protocol was approved
from the Institutional Research Ethics Committee. Clinical
information on the samples is summarized in Table 1 and
Additional file 1: Table S2. The follow-up time of the pri-
mary breast cancer cohort ranged from 4 to 78 months,
and the median follow-up time was 58 months. The per-
centages of tumor purity in sections adjacent to the re-
gions used for RNA extraction were estimated during
routine histopathological analyses.
Real-time PCR (RT-PCR)
Total RNA samples from cell lines and primary tumor
materials were extracted using Trizol reagent (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s in-
structions. The extracted RNA was pretreated with
RNase-free DNase, and 2 μg RNA from each sample was
used for cDNA synthesis primed with random hexamers.
For the PCR amplification of FLOT2 cDNA, an initial
amplification step using FLOT2–specific primers was
performed with denaturation at 95°C for 10 min, followed
by 28 denaturation cycles at 95°C for 60 s, primer
annealing at 58°C for 30 s, and a primer extension phase
at 72°C for 30 s. Upon the completion of the cycling steps,
a final extension step at 72°C for 5 min was performed be-
fore the reaction mixture was stored at 4°C. Real-time
PCR was then employed to determine the fold increase of
FLOT2 mRNA in each of the primary breast tumors rela-
tive to the paired normal breast tissue taken from the
same patient. The primers were designed using Primer
Express v 2.0 software (Applied Biosystems) and are listed
in Additional file 1: Table S1. Expression data were
normalized to the geometric mean of Glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) to control the
variability in expression levels, and all experiments
were performed in triplicate.
Western blotting
Cells at 70% to 80% confluence were washed twice with
ice-cold phosphate-buffered saline (PBS) and lysed on ice
in radio immunoprecipitation assay buffer (RIPA; Cell
Signaling Technology, Danvers, MA) containing complete
protease inhibitor cocktail (Roche Applied Sciences,
Mannheim, Germany). Fresh tissue samples were ground
to powder in liquid nitrogen and lysed with SDS-PAGE
sample buffer. Equal protein samples (20 μg) were sepa-
rated on 10.5% SDS polyacrylamide gels and transferred
to PVDF membranes (Immobilon P, Millipore, Bedford,
MA). Membranes were blocked with 5% fat-free milk in
Tris-buffered saline containing 0.1% Tween-20 (TBST)
for 1 h at room temperature. Membranes were incu-
bated with anti-Flotillin-2 antibody (1:1000, Abcam,
ab96507) overnight at 4°C, and then with horseradish
peroxidase-conjugated goat anti-rabbit IgG (Santa Cruz
Biotechnology, SC-2004). FLOT2 expression was detected
Table 1 Clinicopathological characteristics of patient
samples and expression of FLOT2 in breast cancer
patients
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(Amersham) according to the manufacturer’s instructions.
P84 (Sigma, Saint Louis, MO) was used as a loading
control.
Immunohistochemical (IHC) analysis
Immunohistochemical analysis was performed to study
altered protein expression in 171 human breast cancer
tissues. Briefly, 4-μm-thick paraffin sections of the breast
cancer tissue from the patient were deparaffinized with
xylene and rehydrated. Antigenic retrieval was processed
by submerging the sections into EDTA antigenic retrieval
buffer and microwaving. The samples were then treated
with 3% hydrogen peroxide in methanol to quench en-
dogenous peroxidase activity, followed by incubation with
1% bovine serum albumin to block nonspecific binding.
Sections were then incubated with anti-flotillin-2 rabbit
polyclonal antibody (1:100, Abcam, ab96507) over-
night at 4°C. Normal goat serum was used as a nega-
tive control. After washing, the tissue sections were then
incubated with a biotinylated anti-rabbit secondary anti-
body (Abcam), followed by further incubation with
streptavidin-horseradish peroxidase complex (Abcam).
The tissue sections were immersed in 3-amino-9-ethyl car-
bazole and counterstained with 10% Mayer’s hematoxylin,
dehydrated and mounted in Crystal Mount.
The degree of immunostaining of formalin-fixed,
paraffin-embedded sections was evaluated independently
by two observers who were blinded to the histopatho-
logical features and patient data of the samples. The
scores given by the two independent investigators were
averaged and based on both the proportion of positively-
stained tumor cells and the intensity of staining. The pro-
portion of tumor cells was scored as follows: 1 (<10%
positive tumor cells), 2 (10-50% positive tumor cells), 3
(50-75% positive tumor cells), and 4 (>75% positive tumor
cells). The intensity of staining was graded according to
the following criteria: 0 (no staining); 1 (weak staining =
light yellow), 2 (moderate staining = yellow brown), and 3
(strong staining = brown). The staining index was
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cells and the staining intensity score. Cut-off values for
FLOT2 were chosen on the basis of a measure of hetero-
geneity using the log-rank test with respect to overall sur-
vival (OS). An optimal cut-off value was identified as
follows: a staining index score of ≥6 was used to define tu-
mors with high FLOT2 expression and ≤4 indicated low
FLOT2 expression.
Statistical analysis
The OS rate was the primary endpoint of this study, and
the secondary endpoint was the disease-free survival
(DFS) of patients with breast cancer. The OS was de-
fined as the duration from the date of each patient’s
random assignment to the date of death from any cause
or the censoring of the patient at the date of the last
follow-up. The DFS was defined as the time from
randomization to local, regional, or distant treatment
failure; occurrence of contralateral breast cancer; other
second primary cancer; or death without evidence of
breast or second primary cancer.
All statistical analyses were conducted using the SPSS
16.0 statistical software packages. The relationship between
FLOT2 expression and clinicopathological characteristics
was analyzed by the chi-square test and Fisher’s exact test.
Bivariate correlations between study variables were calcu-
lated by Spearman’s rank correlation coefficients. Survival
curves were plotted by the Kaplan–Meier method and
compared using the log-rank test. Clinicopathological
characteristics which were extensively used to predict
prognosis in clinical practice were evaluated using univari-
ate and multivariate Cox regression analyses. The type of
Cox model chosen by us was forward method. In all cases,
a P-value of less than 0.05 was considered statistically
significant.
Results
FLOT2 is overexpressed in breast cancer cell lines
To evaluate the expression levels of FLOT2 protein and
mRNA in breast cancer cell lines, we used Western blotting
and real-time RT-PCR. The expression of FLOT2 mRNA
and protein were determined for eight breast cancer cell
lines (BT-549, MDA-MB-468, MDA-MB-453, Bcap37,
MCF-7, T47D, ZR-75-1 and MDA-MB-231) and compared
with FLOT2 expression in primary cultured normal mam-
mary epithelial cells (NMEC). FLOT2 protein was highly
expressed in breast cancer cell lines and only weakly
expressed in NMEC (Figure 1A), and FLOT2 mRNA ex-
pression was expressed by at least 5-fold higher levels in
breast cancer cell lines compared to NMEC (Figure 1B).
FLOT2 is overexpressed in breast cancer tissues
To determine whether FLOT2 is also high-expressed in
the human breast cancer clinical samples, we performedRT-PCR and Western blotting analyses on four breast
tumor samples (T) matched with adjacent noncancerous
tissue samples (ANT). As illustrated in Figure 2B,
FLOT2 mRNA was expressed at higher levels in all
breast cancer tissues than in adjacent noncancerous
tissues, with the differential expression level ranging
from 5.1- to 24.4-fold. Consistent with this data, FLOT2
protein was also found to be upregulated in breast can-
cer tissues compared with the surrounding non-tumor
regions (Figure 2A).
FLOT2 overexpression is associated with breast cancer
clinical features
We investigated the status of FLOT2 expression in 171
paraffin-embedded archived breast cancer tissues by im-
munohistochemical staining, including 21 stage I tumors,
92 stage II tumors, 46 stage III tumors and 12 stage IV
tumors Among 171 samples, high FLOT2 protein expres-
sion was detected in 82 samples (48.0%) and weak or no
staining was observed in 89 tumor samples (52.0%,
Table 1). As shown in Figure 2C, no signals or only weak
signals were detected in the adjacent non-cancerous tis-
sues as well as normal breast tissues. In contrast, FLOT2
was highly expressed in breast cancer tissues. The subcel-
lular location of FLOT2 was mainly at the plasma mem-
brane (Figure 3). Furthermore, IHC staining showed that
FLOT2 expression in breast cancer increased with advan-
cing clinical stage (Figure 3). Taken together, these
observations show that high levels of FLOT2 expression
were associated with the clinical development of primary
breast tumors.
We further analyzed the correlation between FLOT2
expression and the clinicopathological characteristics of
patients. As summarized in Table 2, there were no sig-
nificant correlations between the expression level of
FLOT2 protein and patient age, N classification, estrogen
receptor (ER) expression levels or progesterone receptor
(PR) in patients with breast cancer. However, the FLOT2
expression level was markedly associated with clinical
stage (P < 0.001), T classification (P < 0.001), M classifica-
tion (P < 0.001), histological differentiation (P = 0.005) and
ErbB2 expression levels (P = 0.003). These data were fur-
ther confirmed by the results of Spearman correlation
analyses that assessed the correlation between FLOT2
expression and clinicopathological features. As shown
in Table 3, the correlation coefficients between
FLOT2 expression and clinical stage, T classification,
M classification, histological differentiation and ErbB2 ex-
pression levels were 0.306 (P < 0.001), 0.356 (P < 0.001),
0.286 (P < 0.001), 0.243 (P = 0.001) and 0.306 (P < 0.001),
respectively. Taken as a whole, the expression of FLOT2
protein was positively correlated with clinical and patho-
logical stage, T classification, M classification and ErbB-2
expression.
Figure 1 Overexpression of FLOT2 mRNA and protein in breast cancer cell lines. (A and B) Expression of FLOT2 mRNA and protein in
breast cancer cell lines (BT-549, MDA-MB-468, MDA-MB-435, Bcap37, MCF-7, T47D, ZR-75-1 and MDA-MB-231) and NMEC were examined by
Western blotting (A) and qPCR (B). Expression levels were normalized against P84 and GAPDH respectively. Error bars represent the standard
deviation of the mean (SD) calculated from three parallel experiments. *p < 0.05.
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survival
Patient survival analysis showed a clear negative correl-
ation between the level of FLOT2 protein expression
and both the OS and 5-year DFS of patients with breast
cancer (both P < 0.001, Figures 4A, B). The cumulative
OS and DFS rates for patients with high levels of FLOT2
expression were found to be 47.7% and 45.8%, respect-
ively, whereas the rates were 87.3% and 83.7%, respect-
ively, for patients with low or no FLOT2 expression. In
addition, Cox regression revealed that FLOT2 expres-
sion, clinical stage, ErbB2 expression and histological
differentiation were independent prognostic factors for
poor OS outcomes (Table 4).
Moreover, we analyzed the prognostic value of FLOT2
expression in selective patient subgroups stratified
according to tumor grade and T classification (pT),
respectively. The expression of FLOT2 was stronglyassociated with the OS duration of patients with both
early-stage tumors (Stage I or II, log-rank test, P = 0.001)
and late-stage tumors (Stage III and IV, log-rank test, P =
0.001) (Figures 4C and D). However, when it was exam-
ined according to T classification, the impact on outcome
associated with the positive expression of FLOT2 con-
tinued to be more favorable only in the pT1–2 subset
(Figure 4E, log-rank test, P < 0.001) but not in the
pT3-4 subset (Figure 4F, log-rank test, P = 0.135).
Discussion
In this report, we present new evidence that the
overexpression of FLOT2 is associated with poor prog-
nosis in breast cancer patients with both early- and
late-stage disease. Our results clearly showed that the
upregulation of FLOT2 occurred at both the levels of
mRNA and protein in breast cancer cell lines com-
pared to NMEC. Paired breast cancer lesions and adjacent
Figure 3 The expression of FLOT2 protein in breast cancer tissues from patients at different clinical stages.
Figure 2 Overexpression of FLOT2 mRNA and protein in breast cancer tissues. (A) Representative images of Western blotting analyses
of FLOT2 protein expression in four matched pairs of breast cancer (T) and adjacent noncancerous tissues (N). P84 was the loading control.
(B) Average T/N ratios of FLOT2 mRNA expression in paired breast cancer (T) and adjacent noncancerous tissues (N) were quantified by qPCR
and normalized against GAPDH. Error bars represent the standard deviation of the mean (SD) calculated from three parallel experiments.
(C) Immunohistochemical assay of FLOT2 protein expression in four pairs of matched breast cancer tissues. *p < 0.05.
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Table 2 Clinicopathological characteristics of patient samples and expression of FLOT2 in breast cancer patients and
correlation between FLOT2 expression and clinicopathological characteristics of breast cancer patients





Age(y) ≥47 85 47(55.3) 38(44.7) 0.398 0.445
<47 86 42(48.8) 44(51.2)
Clinical stage I 21 16(76.2) 5(23.8) <0.001 <0.001
II 92 53(57.6) 39(42.4)
III 46 20(43.5) 26(56.5)
IV 12 0(0.0) 12(100.0)
T classification T1 35 26(74.3) 9(25.7) <0.001 <0.001
T2 89 51(57.3) 38(42.7)
T3 35 11(31.4) 24(68.6)
T4 12 1(8.3) 11(91.7)
N classification N0 70 41(58.6) 29(41.4) 0.419 0.431
N1 65 33(50.8) 32(49.2)
N2 27 11(40.7) 16(59.3)
N3 9 4(44.4) 5(55.6)
M classification Yes 12 0(0.0) 12(100.0) <0.001 <0.001
No 159 89(56.0) 70(44.0)
Histological
differentiation
Well 9 6(66.7) 3(33.3) 0.005 0.005
Moderate 113 67(59.3) 46(40.7)
Poor 49 16(32.7) 33(67.3)
Expression of ER 0 77 38(49.4) 39(50.6) 0.155 0.165
1 82 41(50.0) 41(50.0)
2 8 7(87.5) 1(12.5)
3 4 3(75.0) 1(25.0)
Expression of PR 0 71 35(49.3) 36(50.7) 0.498 0.527
1 80 41(51.2) 39(48.8)
2 16 11(68.8) 5(31.2)
3 3 1(33.3) 2(66.7)
4 1 1(100.0) 0(0.0)
Expression of
ErbB-2
0 42 30(71.4) 12 (28.6) 0.003 0.002
1 52 30(57.7) 22(42.3)
2 38 18(47.4) 20(52.6)
3 30 9(30.0) 21(70.0)
4 9 2(22.2) 7(77.8)
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sion levels of FLOT2, with cancer lesions displaying rela-
tively higher expression levels of FLOT2. IHC analyses
indicated that FLOT2 was highly expressed in breast can-
cer tissues, which was significantly correlated with the
clinical stage of the disease and unfavorable survival dura-
tions. Our study used biopsy material from both early-
stage (stage I/II) and late-stage (stage III/IV) disease to
analyse the correlation between FLOT2 expression andsurvival times, whereas a similar study by Pust et al. only
used tissue from early-stage (stage I/II) disease [14].
Multivariate analysis revealed that FLOT2 expression
might be an independent prognostic indicator of survival
in breast cancer patients. Our results suggest the import-
ant role of FLOT2 protein in the prognosis of patients
with breast cancer.
FLOT2 has been implicated in several signaling path-
ways in tumor cells. Xenograft experiments revealed that
Table 3 Spearman correlation analysis between FLOT2
and clinical pathologic factors
Variables FLOT2 expression level
Spearman correlation p-Value
Clinical staging 0.306 <0.001
T classification 0.356 <0.001
M classification 0.286 <0.001
Histological differentiation 0.243 0.001
ErbB-2 0.306 <0.001
Figure 4 Kaplan-Meier curves with univariate analysis (log-rank). (A a
expression versus those for cases with low FLOT2 expression levels in all pa
FLOT2 expression versus those for cases with low FLOT2 expression levels.
expression levels versus cases with low FLOT2 expression. (E) OS rate for ca
expression in patients with T1-T2 grade tumors. (F) OS rate for cases with h
in patients with T3-T4 grade tumors.
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the non-metastatic melanoma cell line (SB2) into a highly
tumorigenic metastatic cell line [12]. FLOT2 might pro-
mote PAR-1-induced constitutive signaling through the
BRAF-MAPK-ERK pathway implicated in melanoma pro-
gression [17]. The FLOT2-mediated stabilization of ErbB2
has been associated with tumorigenesis in stage I/II breast
cancer tissues, which is reflected by reduced p-ErbB2 and
p-Akt levels and hyperactivity of the PI3K/AKT/mTOR
pathway in breast tumors [14,18]. Data from a very recent
publication of the genetic ablation of FLOT2 in a well-
established mouse model of mammary tumorigenesis and
metastasis indicated that FLOT2 predicts mammarynd B) OS (A) and 5-year DFS (B) rates for cases with high FLOT2
tients. (C) OS rate for early clinical stage cases (stage I/II) with high
(D) OS rate for late stage cases (stage III/IV) with high FLOT2
ses with high FLOT2 expression versus cases with low FLOT2
igh FLOT2 expression versus that for cases with low FLOT2 expression
Table 4 Univariate and multivariate analyses of various prognostic parameters in patients with breast cancer
Cox-regression analysis (overall survival was modelled)
Univariate analysis Multivariate analysis
No. patients p Regression coefficient (SE) p Relative risk 95% confidence interval
FLOT2 0.002
Low expression 89 <0.001 1.209(0.172) Ref
High expression 82 0.002 4.492 1.740-11.598
Clinical stage <0.001
I 21 Ref
II 92 <0.001 1.618(0.314) 0.824 1.190 0.256-5.522
III 46 0.329 2.236 0.444-11.264
IV 12 0.014 8.594 1.545-47.790
ErbB-2 0.06
0 42 Ref
1 52 <0.001 0.376(0.106) 0.272 0.602 0.244-1.489
2 38 0.237 1.625 0.727-3.629
3 30 0.164 1.811 0.785-4.178
4 9 0.253 2.005 0.608-6.609
Histological differentiation 0.005
Well 9 <0.001 1.283(0.262) Ref
Moderate 113 0.783 0.810 0.181-3.631
Poor 49 0.327 2.105 0.475-9.330
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that FLOT2 may affect the development and progression
of breast cancer through modulating certain signaling
pathways, which may open new avenues into the treat-
ment of breast cancer. As many pathways have been
reported to be hyperactive in breast tumors, the protein
kinases located along the pathway regulated by FLOT2
represent attractive drug targets for breast cancer therap-
ies. However, further studies are required to obtain a de-
tailed picture of FLOT2-related signaling pathways in
breast cancer development.
We further analyzed the relationship between the ex-
pression of FLOT2 and clinical characteristics of patients
affected by breast cancer. There was a significant correl-
ation between FLOT2 expression and the clinical stage,
T classification, M classification, histological differenti-
ation and ErbB2 expression levels, which strongly sug-
gested that the overexpression of FLOT2 would be
useful as an independent marker for the identification of
subsets of breast cancer patients with more aggressive
disease. Moreover, patients in the high FLOT2 expres-
sion group had a 47.7% cumulative 5-year survival rate,
which was significantly lower than that of patients with
low FLOT2 expression levels (87.3%). This finding indi-
cates the possibility of using high expression levels of
FLOT2 as a predictor for prognosis and survival.
In conclusion, this is the first study to highlight the clin-
ical significance of FLOT2 in breast cancer. Higher FLOT2expression levels are a significant prognostic marker of
poor survival in breast cancer patients. A comprehensive
analysis of the molecular mechanism of FLOT2 involve-
ment in the development and progression of breast cancer
is eagerly awaited. Further investigation is also needed to
determine whether FLOT2 could be identified as a target
for novel therapeutics against breast cancer.
Conclusions
In this study, we found that overexpression of FLOT2 is
associated with poor prognosis and reduced survival of
patients with both early-and late-stage disease.
Multivariate analysis showed that FLOT2 protein
levels could be used as an independent prognostic
predictor for breast cancer patients. Therefore, test-
ing the FLOT2 protein level may be useful for strati-
fying patients for novel therapeutic strategies and
establishing rational treatment selection criteria for
patients with breast cancer.Additional file
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